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Research Note: Individual participant data (IPD) meta-analysisA systematic review is a robust method with which to search for,
identify, extract, and synthesise evidence from individual studies to
answer a specific research question.1 Meta-analysis is a statistical
analysis approach used in some systematic reviews to combine
quantitative information across studies, in order to produce overall
summaries of the evidence (eg, of a treatment’s effect). Meta-analyses
are most often conducted using data that has been extracted from
peer-reviewed publications included in systematic reviews; such data
are often called aggregate data, since they represent information
combined across all participants in a particular study. The extracted
data typically include a small number of data pieces from each study,
such as the change in pain (mean, standard deviation) between
treated and untreated study groups, which would allow a treatment
effect estimate and its confidence interval to be calculated. An
aggregate data meta-analysis is a useful approach with which to
summarise the average overall effect of a treatment. However, having
only aggregated group data limits the analyses that are possible, and
in particular makes it problematic to examine relationships where
individual participant-level covariates are of interest. To address this,
another option to synthesise evidence across studies is to use the
original, participant-level study data, using an approach called indi-
vidual participant data (IPD) meta-analysis.
This Research Note describes the steps involved in an IPD meta-
analysis, explains when this research approach is most useful, and
discusses key advantages, challenges and potential future directions.
Table 1 provides definitions of some key terms. Although this
Research Note focuses on meta-analysis of randomised trials evalu-
ating treatment effectiveness, most points apply more broadly.
What is an IPD meta-analysis project and what are the steps?
IPD meta-analysis projects are often considered to be the ‘gold
standard’ for synthesising evidence across studies.2 Table 2 highlights
key differences in the steps of a systematic review with IPD meta-
analysis and a systematic review with a traditional aggregate data
meta-analysis. With an IPD project, raw individual-level data about
each participant (including baseline demographics, health conditions,
prognostic factors and other relevant characteristics, as well as
outcome data) are obtained for each published study, then cleaned,
harmonised and synthesised together. The steps involved in con-
ducting a high-quality IPD project are described below, and additional
detail is provided in a forthcoming handbook.3
Search and selection
A well conducted IPD meta-analysis is part of a systematic review
with clear research questions, inclusion criteria, comprehensive
search, systematic selection, transparent study-level data extraction
and risk of bias assessment. Selection criteria for systematic reviews
using IPD are similar to traditional reviews, typically including pop-
ulation, intervention, comparison and outcome (PICO) criteria, and
may include additional criteria such as sample size or risk of biashttps://doi.org/10.1016/j.jphys.2021.04.001
1836-9553/© 2021 Australian Physiotherapy Association. Published by Elsevier B.V. This is
licenses/by-nc-nd/4.0/).requirements (based on published information). Any reasons for
study exclusion should be clearly documented.4
Accessing individual participant data
IPD can be collected through direct contact with primary study
authors with the use of data-sharing agreements or through data-
sharing platforms (eg, disease-specific data repositories, journal
websites). It is preferable to deal directly with study authors, as the
IPD in a data-sharing platform may be incomplete (eg, not all out-
comes provided) and unavailable to analyse and store locally. IPD
projects should clearly describe how data were requested, collected
and managed (eg, list and define all study-level and participant-level
data that were sought, including baseline and follow-up information).
Data verification, manipulation and replication
Data from each primary study are evaluated, once received, to
confirm comparability to the study publication(s) for descriptive
baseline data, range of included variables and missing observations.
Any discrepancies or missing information from those presented in the
original publication(s) should be clarified with the primary study
authors. Risk of bias classifications should also be updated at this
stage, based on the IPD itself.
Study variable mapping
Once IPD are separately finalised for each study, they need to be
harmonised as far as possible, so that included variables are consis-
tently defined across studies. The homogeneity of the resulting
master dataset depends on data availability of common measure-
ments in the primary studies. Whenever possible, variables measured
continuously should be kept in their continuous data form. Any
standardisation and translation process should be described in detail
in a data management plan.
Analysis
IPD meta-analyses are planned and described a priori and include
descriptive, analytic and, possibly, exploratory analyses. There are
two main approaches to conduct IPD meta-analysis: one-stage or
two-stage. In a two-stage IPD meta-analysis, an estimate of the effect
of interest (eg, treatment effect or interaction between treatment and
participant-level characteristic) is first separately calculated for each
trial; these can be presented in forest plots and then (in the second
stage) combined in a similar manner to a traditional meta-analysis to
produce an overall summary. In one-stage IPD meta-analysis, a single
multi-level model is estimated based on the IPD for all studies
together, while accounting for the clustering of data within each trial.
The one-stage approach is appealing as it simultaneously estimates
multiple parameters in a single step and allows more flexibility in
modelling assumptions. The two-stage approach is appealing as itan open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
Definitions of key terms related to individual participant data meta-analysis.
Term Definition
Meta-analysis Statistical technique for combining quantitative evidence across multiple studies
Aggregate data Information averaged or summarised across a group of participants in a study, such as the overall treatment effect, mean age or the proportion of
females
Typically as reported in publications of the primary studies
Traditionally extracted and used for meta-analysis
Individual participant
data (IPD)
Raw participant-level data collected from the primary studies
Made available for IPD meta-analysis, most commonly from the study researchers
One-stage, two-stage Different statistical approaches to conducting the meta-analysis of IPD
Two-stage: obtain estimates (aggregate data) for each study separately, then pool these across studies




When the treatment effectiveness size differs based on another factor (eg, participant characteristic)
Table 2
Key differences between a traditional aggregate data meta-analysis and an individual participant data (IPD) meta-analysis for treatment effectiveness questions.
Characteristic Traditional aggregate data meta-analysis Differences when using an IPD meta-analysis
Study identification Systematic review with comprehensive search to identify
all studies that answer the research question
None – usually IPD meta-analysis projects also use a systematic review with
comprehensive search to identify all studies that answer the research question.
Study inclusion All available studies, including published and (where identifiable)
unpublished studies
In addition, due to the painstaking nature of retrieving IPD, the project may apply
additional selection criteria to identify a subset of the studies (those low risk of
bias, larger sample size) to prioritise for IPD collection.
Data collected and
analysed
Aggregate data extracted from each study published report,
or sometimes requested from study authors directly
Original participant data are requested, obtained and cleaned from each study
in close collaboration with the original study researchers.
Analysis aims To summarise the average treatment effect across all studies,
for each outcome reported
To quantify any between-study heterogeneity in the treatment
effect, and potentially assess subgroups defined by study or
population-level characteristics (eg, mean age)
In addition, IPD meta-analyses usually aim to model patient-level relationships;
in particular, to obtain treatment effects adjusted for prognostic factors, and to
examine potential treatment effect modification by participant-level
characteristics (treatment-covariate interactions). Furthermore, any outcomes
or time points available in the IPD can be considered, regardless of whether
they were reported upon publication.
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dividual study results, and so eases interpretation. When they use the
same estimation methods and assumptions, one-stage and two-stage
approaches garner generally similar results.5 When most studies
are small (ie, patients and events are few), a one-stage approach is
more exact and therefore preferable. When examining potential
participant-level modifiers of treatment effect, this is performed by
estimating treatment-covariate interactions that quantify how treat-
ment effectiveness varies as participant-level characteristics change.
Riley et al describe how to perform this in a one-stage or two-stage
approach,6 and stress the importance of separating within-trial
from across-trial information to avoid aggregation bias.Reporting
The PRISMA reporting guideline and checklist extension for IPD
(PRISMA-IPD) should be followed for reporting.7When is an IPD meta-analysis the best approach to address a
health research question?
IPD studies are time and resource intensive; it often takes more
than 2 years to obtain, clean and synthesise IPD. The best value for
this considerable expense is when: the aggregate data needed to
answer the research question are not reported/available in the pri-
mary study publications, and/or the IPD are needed to go beyond the
analyses or aims of the original primary studies. These situations
particularly occur in health research questions related to diagnosis,
prognosis or treatment effectiveness, as presented in Table 3, where
participant-level covariates and relationships are of interest for
modelling.Primary study data may be missing for traditional meta-analysis if
a study was not published, or results (or outcomes) were partially or
selectively published. In the latter situation, a larger primary study
sample (eg, if only a study population subset was published) or
additional outcome measures, measured but not reported, may be
available by collecting and analysing IPD.
Larger amounts of more homogeneous data may be available for
syntheses using IPD if exposure, covariate or outcome measures
selected for presentation in publications differ across studies. If study
results are reported across relevant primary studies using different
scales, follow-up time points or cut-off values, these cannot easily be
synthesised using traditional meta-analysis and use of IPD can
potentially allow for standardisation of these measures (eg, Levis
2020; Holden 2021).8,9
Additionally, analyses that require large sample sizes, such as
development and testing of prediction models (eg, Hudda 201910) or
analyses of treatment effect modifiers (eg, Hayden 201911), can
benefit from the use of IPD to increase power. These types of analyses
investigate individual characteristics at a participant level in ways
beyond what is typically planned and feasible for the primary studies.
Very few randomised controlled trials are designed to detect treat-
ment effect modifiers.12 An adequately powered primary study (ie,
trial) to assess treatment effect modification or compare multiple
treatment approaches would need to be extremely large (and more
expensive than IPD).13,14What are the advantages of an IPD meta-analysis project?
There are several advantages of systematic reviews using IPD over
traditional meta-analyses based on aggregate data.15 Systematic re-
views including IPD may improve data availability and quality to
reduce publication bias. Re-analyses of the original raw participant
Table 3
Examples of individual participant data (IPD) meta-analysis projects for different types of questions.
Question type Research question and use of IPD
Diagnostic test accuracy Comparison of two depression scales: assessment of diagnostic accuracy in a manner that was not analysed in the primary studies
(heterogeneous tool measurements; multiple cut-offs rather than only what was published; no previous meta-analysis and only two primary
studies were available to answer this question).8
Predictive modelling Development and validation of a prediction model for fat mass in children: IPD from four primary studies provided sufficient data to develop
and validate a model using routinely available risk factors in existing datasets. The final model including height, weight, age, sex and ethnicity
was reported to have high predictive accuracy.10
Overall prognosis and
prognostic factors
Prognostic factors for non-traumatic adolescent knee pain: IPD enabled selection and harmonising of prognostic factors and both short-term
and long-term outcomes across studies that had not been reported in a homogeneous way.9
Intervention effectiveness Exercise treatment for chronic LBP: this IPD meta-analysis was able to identify potential treatment effect modifiers for exercise therapy that
were not available in the primary studies. There was consistent evidence that heavy work demands and use of pain medications each modify
the effectiveness of exercise therapy compared with other interventions.11
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participant subgroups, or definition of outcomes, and can reduce risk
of bias concerns. Also, unpublished trials or unreported/incomplete
data (and outcomes) can be included if IPD are available for these
studies.
IPD meta-analysis can enable better investigation of subgroups
and treatment effect modifiers, considering effects in participants
with different characteristics (disentanglement of participant-level
and study-level sources of heterogeneity in treatment effect). The
greater power for these types of analyses is difficult to achieve from
individual studies or from aggregate data. Traditional meta-analysis
can explore treatment-covariate interactions by meta-regression on
study-level characteristics. These analyses are limited to study/
population-level data (with limited variation at the aggregate
level – eg, mean age) and are prone to study-level confounding
(causing aggregation bias).6 IPD gives more power, a larger number of
individual-level covariates and a wider range of covariate values. IPD
meta-analysis enables direct derivation of desired information at
different time points, the correlation amongst multiple outcomes or
time-points to be accounted for in the analysis (which can lead to
efficiency gains),16 the modelling of continuous outcomes and vari-
ables on their continuous scale (thereby avoiding the use of arbitrary
cut-off values), and the adjustment for prognostic factors and effect
modifiers to improve consistency for network meta-analysis.17 All of
these advantages have the potential to provide better data, which can
enhance clinical decision-making.
The collaborative nature of IPD projects provides the advantage of
a larger team, with input and engagement on the project from
experienced trialists. Furthermore, this may enable more unpublished
data to be included, facilitate prospective planning of multisite and
multi-country trials, support standardisation of prognostic factor
measurement, and foster sharing of data through accessible
repositories.18What are the challenges of an IPD meta-analysis project?
A potential limitation of IPD studies is the inconsistent availability
and measurement of some individual variables. This can limit the
ability to include prognostic factors or to assess all potential treat-
ment effect modifiers with the most valid and reliable measures.
IPD meta-analysis projects may not be able to retrieve all study
data; selection bias/availability bias may be a challenge if relevant
data are not available for all trials.19 To address this challenge,
where possible, IPD meta-analysis should compare or combine
data from the included IPD trials with aggregate data from other
trials.20 IPD meta-analysis should report the proportion of eligible
included studies and reasons for unavailability. The reader should
consider if bias was likely to be introduced by unavailable studies
and/or data.
An additional challenge of the IPD approach, acknowledged by all
researchers with experience in this study design, is the considerable
amount of time and effort that is involved in gathering, testing and
compiling data from individual studies.21 Relative to the often-insurmountable cost to prospectively collect adequate data for ef-
fect modification analyses, IPD analyses are very efficient.
The future of IPD meta-analysis
Most systematic reviews summarise aggregate data.22 However,
availability of IPD is likely to increase in the future due to an increase
in data repositories, data-sharing initiatives and expectations from
research funders. The International Committee of Medical Journal Edi-
tors (ICMJE) member journals required a data-sharing statement as of
July 2018, and a data-sharing plan for trials registered after January
2019. While they do not require data sharing, they have established
minimal requirements intended to move the medical research field
toward the goal of universal data sharing. In addition to top-down
mandates, there is increased recognition of the academic value of
dataset development and sharing. Data sharing may increase the
feasibility and conduct of IPD meta-analysis through more readily
available datasets, and through a reduction in current barriers
(ethical, regulatory).23 There is still a long way to go to achieve this;
even with a pandemic, the willingness to share IPD is low.24
Future prospective coordination and collaboration for more
consistent data collection will make the efforts of IPD meta-analysis
more beneficial to the clinical community.18 IPD meta-analysis is an
ethical, efficient research method that reuses data and enables in-
vestigations of participant-level characteristics, treatment effect and
outcomes that would otherwise not be feasible with most current
trial sizes. They generate additional knowledge from existing studies,
thereby reducing the need for more primary studies and limiting
research waste. The clinical utility of IPD meta-analysis depends upon
well-conducted and planned trials, the collection of a set of minimum
variables, and ethics and informed consent in primary trials that
allow for future data sharing.
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